Merck KGaA raises forex-adj profit guidance on drugs, lab gear

Reuters08-07

UPDATE 1-<a href="https://laohu8.com/S/MKGAF">Merck KGaA</a> raises forex-adj profit guidance on drugs, lab gear

Adds Q2 earnings, background

FRANKFURT Aug 7 (Reuters) - Germany's Merck KGaA MRCG.DE on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign exchange headwinds, citing a strong performance at its pharmaceuticals and lab equipment businesses.

In a statement, Merck predicted organic growth in earnings before interest, tax, depreciation and amortisation, adjusted for one-off items, of 4% to 8%, where it had previously seen a range between 2% and 7%. Cost cuts were also a driver, it added.

Hit by a weak U.S. dollar that is weighing on the value of Merck's overseas revenues, second-quarter adjusted EBITDA slipped 3% to 1.46 billion euros ($1.70 billion), below an analyst consensus of 1.52 billion posted on the company's website.

The company, also a maker of materials for semiconductor manufacturing, narrowed its guidance range for organic sales growth to 2% to 5%, where it had previously seen a gain of 2% to 6%.

Merck in April struck a deal to buy U.S. biotech company SpringWorks Therapeutics SWTX.O for $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring drug patents.

($1 = 0.8568 euros)

(Reporting by Ludwig Burger, editing by Kirsti Knolle)

((ludwig.burger@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557253587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 13:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557253587","market":"us","top_or_hot":-1,"title":"Merck KGaA raises forex-adj profit guidance on drugs, lab gear","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-<a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> raises forex-adj profit guidance on drugs, lab gear</title></head><body><p>Adds <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings, background</p><p>\n<span>FRANKFURT Aug 7 (Reuters)</span><span> - </span>Germany's <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> <span>MRCG.DE</span> on Thursday raised its full-year operating earnings guidance, excluding the effect of <span>harsh</span> foreign exchange headwinds, citing a strong performance at its pharmaceuticals and lab equipment businesses. </p><p>In a statement, Merck predicted organic growth in earnings before interest, tax, depreciation and amortisatio<span>n</span>, adjusted for one-off items, of 4% to 8%, where it had previously seen a range between 2% and 7%. <span>Cost cuts were also a driver, it added. </span> </p><p><span>Hit by a weak U.S. dollar that is weighing on the value of Merck's overseas revenues, second-quarter adjusted EBITDA slipped 3% to 1.46 billion euros ($1.70 billion), below an analyst consensus of 1.52 billion posted on the company's website.</span></p><p>\n<span>The company, also a maker of materials for semiconductor manufacturing, narrowed its guidance range for organic sales growth to 2% to 5%, where it had previously seen a gain of 2% to 6%.</span>\n</p><p>\n<span>Merck in April struck a </span>\n<span>deal</span>\n<span> to buy U.S. biotech company SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SWTX.O</span> for $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring drug patents.  </span></p><p>($1 = 0.8568 euros)</p><p> (Reporting by Ludwig Burger, editing by Kirsti Knolle)</p><p> ((ludwig.burger@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck KGaA raises forex-adj profit guidance on drugs, lab gear</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck KGaA raises forex-adj profit guidance on drugs, lab gear\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 13:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-<a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a> raises forex-adj profit guidance on drugs, lab gear</title></head><body><p>Adds <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings, background</p><p>\n<span>FRANKFURT Aug 7 (Reuters)</span><span> - </span>Germany's <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a> <span>MRCG.DE</span> on Thursday raised its full-year operating earnings guidance, excluding the effect of <span>harsh</span> foreign exchange headwinds, citing a strong performance at its pharmaceuticals and lab equipment businesses. </p><p>In a statement, Merck predicted organic growth in earnings before interest, tax, depreciation and amortisatio<span>n</span>, adjusted for one-off items, of 4% to 8%, where it had previously seen a range between 2% and 7%. <span>Cost cuts were also a driver, it added. </span> </p><p><span>Hit by a weak U.S. dollar that is weighing on the value of Merck's overseas revenues, second-quarter adjusted EBITDA slipped 3% to 1.46 billion euros ($1.70 billion), below an analyst consensus of 1.52 billion posted on the company's website.</span></p><p>\n<span>The company, also a maker of materials for semiconductor manufacturing, narrowed its guidance range for organic sales growth to 2% to 5%, where it had previously seen a gain of 2% to 6%.</span>\n</p><p>\n<span>Merck in April struck a </span>\n<span>deal</span>\n<span> to buy U.S. biotech company SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SWTX.O</span> for $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring drug patents.  </span></p><p>($1 = 0.8568 euros)</p><p> (Reporting by Ludwig Burger, editing by Kirsti Knolle)</p><p> ((ludwig.burger@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BLSP4452.SGD","symbol_name":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ0E3:1","article_id":"2557253587","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557253587","pubTimestamp":1754544055,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-Merck KGaA raises forex-adj profit guidance on drugs, lab gearAdds Q2 earnings, background. FRANKFURT Aug 7  - Germany's Merck KGaA MRCG.DE on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign exchange headwinds, citing a strong performance at its pharmaceuticals and lab equipment businesses. In a statement, Merck predicted organic growth in earnings before interest, tax, depreciation and amortisation, adjusted for one-off items, of 4% to 8%, where it had previously seen a range between 2% and 7%. Cost cuts were also a driver, it added.  Hit by a weak U.S. dollar that is weighing on the value of Merck's overseas revenues, second-quarter adjusted EBITDA slipped 3% to 1.46 billion euros , below an analyst consensus of 1.52 billion posted on the company's website.The company, also a maker of materials for semiconductor manufacturing, narrowed its guidance range for organic sales growth to 2% to 5%, where it had previously seen a gain","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4007":"制药","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","MRK":"默沙东","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4559":"巴菲特持仓","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SWTX":"SpringWorks Therapeutics, Inc.","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC"},"translate_title":"默克公司提高了药品和实验室设备的外汇调整利润指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9,"MRK":0.9},"content_text":"UPDATE 1-Merck KGaA raises forex-adj profit guidance on drugs, lab gearAdds Q2 earnings, background\nFRANKFURT Aug 7 (Reuters) - Germany's Merck KGaA MRCG.DE on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign exchange headwinds, citing a strong performance at its pharmaceuticals and lab equipment businesses. In a statement, Merck predicted organic growth in earnings before interest, tax, depreciation and amortisation, adjusted for one-off items, of 4% to 8%, where it had previously seen a range between 2% and 7%. Cost cuts were also a driver, it added.  Hit by a weak U.S. dollar that is weighing on the value of Merck's overseas revenues, second-quarter adjusted EBITDA slipped 3% to 1.46 billion euros ($1.70 billion), below an analyst consensus of 1.52 billion posted on the company's website.\nThe company, also a maker of materials for semiconductor manufacturing, narrowed its guidance range for organic sales growth to 2% to 5%, where it had previously seen a gain of 2% to 6%.\n\nMerck in April struck a \ndeal\n to buy U.S. biotech company SpringWorks Therapeutics SWTX.O for $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring drug patents.  ($1 = 0.8568 euros) (Reporting by Ludwig Burger, editing by Kirsti Knolle) ((ludwig.burger@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557253587","isCrawlerRequest":true}